Ultime notizie per Qualis Innovations (OTC:QLIS) Azioni

Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality-agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.

QUALIS INNOVATIONS INC by Qualis Innovations, Inc.

Qualis Innovations Inc

News

Guidance

EXAS

Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.34 by 17.65 percent. The company reported quarterly sales of $718.100 million which missed the analyst consensus estimate of $724.700 million by 0.91 percent. This is a 6.02 percent increase over sales of $677.300 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand Q3 2024 Adj. EPS $0.40 Beats $0.34 Estimate, Sales $718.100M Miss $724.700M Estimate

Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(1.11) by 25.23 percent. This is a 8.79 percent increase over losses of $(0.91) per share from the same period last year.

PCVX

Vaxcyte Q3 EPS $(0.83) Beats $(1.11) Estimate

Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) raises FY2024 sales outlook from $201.00 million-211.00 million to $204.00 million-211.00 million.

TMCI

Treace Medical Concepts Raises FY2024 Sales Guidance from $201.00M-211.00M to $204.00M-211.00M

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.84 by 16.67 percent. The company reported quarterly sales of $504.600 million which beat the analyst consensus estimate of $502.669 million by 0.38 percent. This is a 5.37 percent increase over sales of $478.900 million the same period last year.

MASI

Masimo Q3 2024 Adj. EPS $0.98 Beats $0.84 Estimate, Sales $504.600M Beat $502.669M Estimate

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. The company reported quarterly sales of $709.00 million which missed the analyst consensus estimate of $717.66 million by 1.21 percent. This is a 12.84 percent increase over sales of $628.34 million the same period last year.

Exact Sciences Q3 2024 GAAP EPS $(0.21) Misses $(0.20) Estimate, Sales $709.00M Miss $717.66M Estimate

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $62.400 million which beat the analyst consensus estimate of $58.025 million by 7.54 percent. This is a 152.63 percent increase over sales of $24.700 million the same period last year.

NCMI

National CineMedia Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $62.400M Beat $58.025M Estimate

Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) lowers FY2025 sales outlook from $450.00 million-490.00 million to $430.00 million-470.00 million vs 458.78M analyst estimates.

AVNW

Aviat Networks Lowers FY2025 Sales Guidance from $450.00M-490.00M to $430.00M-470.00M vs 458.78M Est.

Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 3.95 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $33.251 million which beat the analyst consensus estimate of $32.517 million by 2.26 percent. This is a 47.76 percent increase over sales of $22.504 million the same period last year.

RYTM

Rhythm Pharmaceuticals Q3 2024 GAAP EPS $(0.73) Beats $(0.82) Estimate, Sales $33.251M Beat $32.517M Estimate

Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. The company reported quarterly sales of $167.900 million which missed the analyst consensus estimate of $171.192 million by 1.92 percent. This is a 4.01 percent decrease over sales of $174.909 million the same period last year.

CRCT

Cricut Q3 2024 Adj. EPS $0.05, Inline, Sales $167.900M Miss $171.192M Estimate

Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) reported quarterly earnings of $1.56 per share which beat the analyst consensus estimate of $1.33 by 17.29 percent. This is a 3.31 percent increase over earnings of $1.51 per share from the same period last year. The company reported quarterly sales of $153.87 million which beat the analyst consensus estimate of $150.70 million by 2.10 percent. This is a 8.36 percent increase over sales of $142.00 million the same period last year.

QLYS

Qualys Q3 2024 Adj EPS $1.56 Beats $1.33 Estimate, Sales $153.87M Beat $150.70M Estimate

PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.01 by 200 percent. The company reported quarterly sales of $15.256 million which beat the analyst consensus estimate of $14.822 million by 2.93 percent. This is a 23.03 percent increase over sales of $12.400 million the same period last year.

PAYS

PaySign Q3 2024 GAAP EPS $0.03 Beats $0.01 Estimate, Sales $15.256M Beat $14.822M Estimate

RARE

Ultragenyx Pharmaceutical Sees FY24 Revenue $530M-$550M Vs $536.8M Est

Share Repurchase Program:
The Company's board of directors (the "Board") has approved a new share repurchase program (the "2024 Share Repurchase Program") pursuant to which the Company is authorized to repurchase up to $100.0 million in shares of the Company's common stock, inclusive of fees and commissions. This program replaces the Company's previous share repurchase program adopted in 2021, under which $9.4 million remained available for repurchase. The 2024 Share Repurchase Program is effective immediately and does not have an expiration date.
Repurchases under the 2024 Share Repurchase Program may be made, from time to time, in amounts and prices the Company deems appropriate and may be made pursuant to a trading plan intended to qualify under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Repurchases by the Company under the 2024 Share Repurchase Program will be subject to general market and economic conditions, applicable legal requirements and other considerations. The 2024 Share Repurchase Program may be suspended, modified or discontinued by the Board at any time without prior notice at the Company's discretion.

Buybacks

Grocery Outlet Holding Corp. Has Approved A New Share Repurchase Program Pursuant To Which The Company Is Authorized To Repurchase Up To $100M In Shares Of The Company's Common Stock,

Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $3.221 billion which Beat the analyst consensus estimate. This is a 11.54 percent decrease over sales of $3.64 billion the same period last year.

LUMN

Lumen Technologies Q3 2024 Adj EPS $(0.13) Misses $(0.09) Estimate, Sales $3.221B Beat $3.218B Estimate

Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.18) by 144.44 percent. The company reported quarterly sales of $854.000 thousand which missed the analyst consensus estimate of $6.477 million by 86.81 percent. This is a 24.85 percent increase over sales of $684.000 thousand the same period last year.

EOSE

Eos Energy Enterprises Q3 2024 Adj. EPS $(0.44) Misses $(0.18) Estimate, Sales $854.000K Miss $6.477M Estimate

Momentum investing is all about the idea of following a stock&#39;s recent trend, which can be in either direction. In the &#39;long&#39; context, investors will essentially be &quot;buying high, but hoping to sell even higher.&quot; And for investors following this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the <a href="https://www.zacks.com/education/stock-style-scores/momentum-trading" target="_blank">Zacks Style Scores</a>, helps address this issue for us.
Below, we take a look at U.S. Bancorp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usb#NYSE">USB</a>), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. U.S. Bancorp currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
<h3>Set to Beat the Market?</h3>
In order to see if USB is a promising momentum pick, let&#39;s examine some Momentum Style elements to see if this company holds up.
Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For USB, shares are up 0.21% over the past week while the Zacks Banks - Major Regional industry is up 0.33% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 6.12% compares favorably with the industry&#39;s 4.51% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of U.S. Bancorp have risen 13.79%, and are up 33.8% in the last year. On the other hand, the S&amp;P 500 has only moved 7.29% and 32.85%, respectively.
Investors should also pay attention to USB&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. USB is currently averaging 8,694,755 shares for the last 20 days.
<h3>Earnings Outlook</h3>
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with USB.
Over the past two months, 6 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost USB&#39;s consensus estimate, increasing from $3.86 to $3.92 in the past 60 days. Looking at the next fiscal year, 8 estimates have moved upwards while there have been 1 downward revision in the same time period.
<h3>Bottom Line</h3>
Given these factors, it shouldn&#39;t be surprising that USB is a #2 (Buy) stock and boasts a Momentum Score of B. If you&#39;re looking for a fresh pick that&#39;s set to soar in the near-term, make sure to keep U.S. Bancorp on your short list.
<a href="https://www.zacks.com/stock/news/2364640/u-s-bancorp-usb-is-a-great-momentum-stock-should-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2364640">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

Markets

Trading Ideas

General

U.S. Bancorp Is A Great Momentum Stock: Should You Buy?

Contracts

Eos Energy Announced A New Agreement With City Utilities To Provide 216 MWh Of Energy Storage For Two Project Sites In Missouri: Terms Not Disclosed

National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) sees Q4 sales of $82.000 million-86.000 million vs $89.27 million estimate.

National CineMedia Sees Q4 Sales $82.000M-86.000M vs $89.27M Est.

Outlook:
The Company is updating key guidance figures for fiscal 2024 as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Previous</td>
<td>Current</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>New store openings, net(2)</td>
<td>62 to 64</td>
<td>66</td>
</tr>
<tr>
<td>Net sales</td>
<td>$4.30 billion to $4.35 billion</td>
<td>slightly above $4.35 billion</td>
</tr>
<tr>
<td>Comparable store sales increase</td>
<td>~3.5%</td>
<td>~2.4%</td>
</tr>
<tr>
<td>Gross margin</td>
<td>~30.5%</td>
<td>~30.4%</td>
</tr>
<tr>
<td>Adjusted EBITDA(1)</td>
<td>$252 million to $260 million</td>
<td>$237 million to $242 million</td>
</tr>
<tr>
<td>Adjusted diluted earnings per share(1)</td>
<td>$0.89 to $0.95</td>
<td>$0.77 to $0.80</td>
</tr>
<tr>
<td>Capital expenditures (net of tenant improvement allowances)</td>
<td>~$200 million</td>
<td>~$200 million</td>
</tr>
</tbody>
</table>
</figure>

Grocery Outlet Holding Corp. Updates FY24 EPS Guidance From $0.89-$0.95 To $0.77-$0.80 Vs $0.88 Est.; Revenue From $4.30B-$4.35B To Slightly Above $4.35B Vs $4.37B Est.

Comments

Qualis Innovations

Notizie

Ultime notizie per Qualis Innovations (OTC:QLIS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO